Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Relief Therapeutics Holdings AG

< Previous 1 2 3 Next >
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers RLFTF RLFTY
Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF RLFTY
Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers RLFTF RLFTY
Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers RLFTF RLFTY
Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers RLFTF RLFTY
Relief Therapeutics Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers RLFTF RLFTY
Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Death
Exposures COVID-19 Death
Tickers RLFTF RLFTY
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers RLFTF RLFTY
Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF RLFTY
Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Lawsuit
Exposures Financial Legal
Tickers RLFTF RLFTY
Relief Comments on Lawsuit Filed Against It by NeuroRx
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Lawsuit
Exposures Financial Legal
Tickers RLFTF RLFTY
Relief Reports US Collab. Partner Announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
Tickers RLFTF RLFTY
Relief Therapeutics to Participate in Virtual Investor Conferences in January
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers RLFTF RLFTY
Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
Tickers RLFTF RLFTY
Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF RLFTY
Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF RLFTY
Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers RLFTF RLFTY
Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Tickers RLFTF RLFTY
Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
From Relief Therapeutics Holdings AG
Via AccessWire
Tickers RLFTF RLFTY
Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF RLFTY
Relief Therapeutics Announces Executive Changes
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF RLFTY
Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF RLFTY
Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence COVID-19 Intellectual Property
Tickers RLFTF RLFTY
Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF RLFTY
Relief Therapeutics Launches Level 1 ADR Program in the United States
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Reports that its U.S. Collaboration Partner has Announced it has Received a U.S. Food and Drug Administration Review of Aviptadil Manufacturing Information
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Tickers RLFTF
Relief Provides Corporate Update and Outlines Plans to Advance its Diversified Portfolio of Pipeline Candidates, Including RLF-100(TM) (Aviptadil)
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
Tickers RLFTF
Relief Therapeutics Announces Transitions in Commercial Organization to Implement Next Phase of Corporate Development
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers RLFTF
Relief Reports U.S. Collaboration Partner's Emergency Use Authorization Request for ZYESAMI/RLF-100 (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by U.S. FDA
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
Relief Therapeutics Takes First Step to Create an ADR Program in the United States by Filing a Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Tickers RLFTF
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.